Validation of the 2025 American Thyroid Association (ATA) risk stratification system in a cohort of patients with papillary thyroid carcinoma
Authors' conclusion
In a real-life context, the 2025 ATA risk stratification system led to a shift toward higher-risk classes. The newly defined "low-intermediate-risk" class was the only class that significantly diverged from the classes of the 2015 stratification, with a risk of structural recurrence between the prior "low-risk" and "intermediate-risk" classes
Study context
- Population
- Papillary thyroid cancer (PTC) patients with complete histopathological and final disease outcome data, tertiary care center
- Participants
- 670 patients
- Exposure
- 2025 ATA vs 2015 ATA risk stratification system
- Outcome
- Redistribution of patients classified by the 2015 ATA system according to the 2025 version, and impact of reclassification on final disease outcome prediction
Methodological detailssingle-centre, tertiary care center
- Single-centre
- Tertiary care center
Main finding
As reported in the abstract
Reclassification by 2025 ATA risk stratification
Proportion of "low-risk" PTC decreased
22.2%
"Intermediate-risk" PTC increased
41.7
"High-risk" PTC increased
14.9%
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Structural disease persistence: cross-comparison of 2025 vs 2015 classes2025 "low-intermediate-risk" vs 2015 "low-risk" · higher risk with 2025 "low-intermediate-risk" | P = 0.003 |
| Structural disease persistence: cross-comparison of 2025 vs 2015 classes2025 "low-intermediate-risk" vs 2015 "intermediate-risk" · lower risk with 2025 "low-intermediate-risk" | P = 0.012 |
Structural disease persistence: cross-comparison of 2025 vs 2015 classes
- Structural disease persistence comparable in 2025 and 2015 "low-risk" and "high-risk" classes
- 2025 "intermediate-high-risk" class similar to former "intermediate-risk" class
Original publication
Validation of the 2025 ATA risk stratification system in a cohort of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. Published 17 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →